MA46752A - Traitement de maladies du snc au moyen de stimulateurs de gcs - Google Patents
Traitement de maladies du snc au moyen de stimulateurs de gcsInfo
- Publication number
- MA46752A MA46752A MA046752A MA46752A MA46752A MA 46752 A MA46752 A MA 46752A MA 046752 A MA046752 A MA 046752A MA 46752 A MA46752 A MA 46752A MA 46752 A MA46752 A MA 46752A
- Authority
- MA
- Morocco
- Prior art keywords
- gcs
- stimulators
- treatment
- cns diseases
- cns
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662419059P | 2016-11-08 | 2016-11-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46752A true MA46752A (fr) | 2019-09-18 |
Family
ID=60452769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046752A MA46752A (fr) | 2016-11-08 | 2017-11-07 | Traitement de maladies du snc au moyen de stimulateurs de gcs |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11690828B2 (fr) |
| EP (1) | EP3538096B1 (fr) |
| JP (2) | JP7150740B2 (fr) |
| KR (1) | KR102475124B1 (fr) |
| CN (1) | CN110267658B (fr) |
| AU (2) | AU2017359018C1 (fr) |
| BR (1) | BR112019009449A2 (fr) |
| CA (1) | CA3042548A1 (fr) |
| CL (1) | CL2019001256A1 (fr) |
| EA (1) | EA201991147A1 (fr) |
| ES (1) | ES2972711T3 (fr) |
| IL (1) | IL266275B2 (fr) |
| MA (1) | MA46752A (fr) |
| MX (2) | MX2019005342A (fr) |
| PH (1) | PH12019501016A1 (fr) |
| SG (1) | SG10202104865UA (fr) |
| TW (1) | TWI812601B (fr) |
| WO (1) | WO2018089328A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3538520A2 (fr) * | 2016-11-08 | 2019-09-18 | Cyclerion Therapeutics, Inc. | Stimulateurs de sgc |
| US11389449B2 (en) | 2017-09-14 | 2022-07-19 | Cyclerion Therapeutics, Inc. | Treatment of metabolic syndrome with an sGC stimulator |
| BR112021000358A2 (pt) | 2018-07-11 | 2021-04-06 | Cyclerion Therapeutics, Inc. | Uso de estimulantes de sgc para o tratamento de distúrbios mitocondriais |
| US20220087970A1 (en) * | 2019-01-18 | 2022-03-24 | The Johns Hopkins University | Prevention of anesthetic-induced neurocognitive dysfunction |
| US20230012071A1 (en) * | 2019-12-05 | 2023-01-12 | Zydus Lifesciences Limited | Modified release pharmaceutical compositions of riociguat |
| CN112924573B (zh) * | 2021-01-21 | 2022-01-04 | 山东英盛生物技术有限公司 | 一种阿比多尔、利巴韦林、氯喹的hplc-ms/ms检测方法 |
| WO2023130028A1 (fr) * | 2021-12-31 | 2023-07-06 | Tenax Therapeutics, Inc. | Formulations orales de levosimendan pour le traitement de l'hypertension pulmonaire avec insuffisance cardiaque à fraction d'éjection préservée |
| WO2024163888A1 (fr) * | 2023-02-03 | 2024-08-08 | R.P. Scherer Technologies, Llc | Capsules pharmaceutiques osmotiques |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3995631A (en) | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
| US4203440A (en) | 1978-10-23 | 1980-05-20 | Alza Corporation | Device having variable volume chamber for dispensing useful agent |
| US4627850A (en) | 1983-11-02 | 1986-12-09 | Alza Corporation | Osmotic capsule |
| EP0192963B1 (fr) | 1985-02-27 | 1988-07-20 | Werkzeugmaschinenfabrik Oerlikon-Bührle AG | Installation de mesure des vibrations d'une transmission à roues coniques dentées en spirale sur une machine d'essai de roues dentées |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Hydrogel-operated release devices |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5324280A (en) | 1990-04-02 | 1994-06-28 | Alza Corporation | Osmotic dosage system for delivering a formulation comprising liquid carrier and drug |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| JP2928079B2 (ja) | 1994-02-14 | 1999-07-28 | 永信薬品工業股▲ふん▼有限公司 | １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途 |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| DE19744026A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| WO2000002851A1 (fr) | 1998-07-08 | 2000-01-20 | Aventis Pharma Deutschland Gmbh | N-arylamides d'acide sulfonylaminocarboxylique a substitution soufre, preparation et utilisation de ces derniers, preparations pharmaceutiques contenant ces composes |
| DE19830430A1 (de) | 1998-07-08 | 2000-01-13 | Hoechst Marion Roussel De Gmbh | Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| GB9824310D0 (en) | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| ATE260642T1 (de) | 1998-12-17 | 2004-03-15 | Alza Corp | Umwandlung von flüssigkeitsgefüllten gelatinkapseln in systeme mit gesteuerter wirkstoffabgabe durch mehrfache beschichtungen |
| US6342249B1 (en) | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
| DE19942809A1 (de) | 1999-09-08 | 2001-03-15 | Bayer Ag | Verfahren zur Herstellung substituierter Pyrimidinderivate |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10216145A1 (de) | 2002-04-12 | 2003-10-23 | Bayer Ag | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| JP2007501217A (ja) | 2003-08-04 | 2007-01-25 | ファイザー・プロダクツ・インク | コレステリルエステル転送タンパク質阻害剤を制御放出し、そしてＨＭＧ−ＣｏＡレダクターゼ阻害剤を即時放出する投薬形態 |
| DE102006020327A1 (de) * | 2006-04-27 | 2007-12-27 | Bayer Healthcare Ag | Heterocyclisch substituierte, anellierte Pyrazol-Derivate und ihre Verwendung |
| EP2197551B1 (fr) | 2007-09-06 | 2016-12-28 | Merck Sharp & Dohme Corp. | Activateurs de la guanylate cyclase soluble |
| JP2011510082A (ja) | 2008-01-24 | 2011-03-31 | メルク・シャープ・エンド・ドーム・コーポレイション | アンジオテンシンｉｉ受容体拮抗薬 |
| AU2009322836B2 (en) | 2008-11-25 | 2013-04-04 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| CA2753434C (fr) | 2009-02-26 | 2014-07-15 | Merck Sharp & Dohme Corp. | Activateurs solubles de guanylate cyclase |
| WO2011119518A1 (fr) | 2010-03-25 | 2011-09-29 | Merck Sharp & Dohme Corp. | Activateurs de guanylate cyclase solubles |
| MA34330B1 (fr) | 2010-05-27 | 2013-06-01 | Merck Sharp & Dohme | Activateurs de guanylate cyclase soluble |
| EP2632551B1 (fr) | 2010-10-28 | 2016-07-06 | Merck Sharp & Dohme Corp. | Activateurs de la guanylate cyclase soluble |
| EA201891416A1 (ru) * | 2015-12-14 | 2018-12-28 | Айронвуд Фармасьютикалз, Инк. | ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ ДИСФУНКЦИИ ЖЕЛУДОЧНО-КИШЕЧНОГО СФИНКТЕРА |
| WO2017108441A1 (fr) | 2015-12-22 | 2017-06-29 | Universiteit Maastricht | Traitement de la déficience cognitive à l'aide d'un stimulateur de la sgc |
| WO2017121700A1 (fr) | 2016-01-15 | 2017-07-20 | Bayer Pharma Aktiengesellschaft | Dérivés de 1h-pyrazolo[3,4-b]pyridine 1,3-disubstitués et leur utilisation en tant que stimulateurs de la guanylacte cyclase soluble |
| PE20190607A1 (es) * | 2016-09-02 | 2019-04-23 | Ironwood Pharmaceuticals Inc | Estimuladores de sgc |
-
2017
- 2017-11-07 EP EP17804374.1A patent/EP3538096B1/fr active Active
- 2017-11-07 AU AU2017359018A patent/AU2017359018C1/en active Active
- 2017-11-07 MA MA046752A patent/MA46752A/fr unknown
- 2017-11-07 IL IL266275A patent/IL266275B2/en unknown
- 2017-11-07 CA CA3042548A patent/CA3042548A1/fr active Pending
- 2017-11-07 WO PCT/US2017/060299 patent/WO2018089328A1/fr active Application Filing
- 2017-11-07 EA EA201991147A patent/EA201991147A1/ru unknown
- 2017-11-07 TW TW106138467A patent/TWI812601B/zh active
- 2017-11-07 SG SG10202104865UA patent/SG10202104865UA/en unknown
- 2017-11-07 MX MX2019005342A patent/MX2019005342A/es unknown
- 2017-11-07 US US16/348,359 patent/US11690828B2/en active Active
- 2017-11-07 CN CN201780080543.0A patent/CN110267658B/zh active Active
- 2017-11-07 ES ES17804374T patent/ES2972711T3/es active Active
- 2017-11-07 JP JP2019545723A patent/JP7150740B2/ja active Active
- 2017-11-07 BR BR112019009449A patent/BR112019009449A2/pt not_active IP Right Cessation
- 2017-11-07 KR KR1020197016351A patent/KR102475124B1/ko active IP Right Grant
-
2019
- 2019-05-07 CL CL2019001256A patent/CL2019001256A1/es unknown
- 2019-05-07 MX MX2022010852A patent/MX2022010852A/es unknown
- 2019-05-08 PH PH12019501016A patent/PH12019501016A1/en unknown
-
2022
- 2022-08-08 JP JP2022126467A patent/JP2022160605A/ja active Pending
-
2023
- 2023-05-12 US US18/196,826 patent/US20230381153A1/en active Pending
- 2023-11-22 AU AU2023270267A patent/AU2023270267A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46752A (fr) | Traitement de maladies du snc au moyen de stimulateurs de gcs | |
| MA47095A (fr) | Traitement du palais mou | |
| DK3360508T3 (da) | Hjælpeanordning til dental behandling | |
| DK3777855T3 (da) | Fremgangsmåder til behandling af fibrotiske sygdomme | |
| MA48996A (fr) | Méthodes de traitement de maladies neurodégénératives | |
| JP2016208024A5 (ja) | 電極の作製方法 | |
| ZA201807084B (en) | Methods of treatment of cholestatic diseases | |
| DK3240895T3 (da) | Sammensætninger og fremgangsmåder til proteinglykosylering | |
| MA52789A (fr) | Méthodes de traitement du cancer avec des anticorps anti-pd-1 | |
| EA201890185A1 (ru) | Способы лечения опосредованных гепсидином нарушений | |
| DK3153148T3 (da) | Apparat til seksuel stimulation | |
| MA44126A (fr) | Méthodes de traitement de maladies et troubles pulmonaires | |
| EA201891468A1 (ru) | Композиции и способы для снижения экспрессии tau | |
| MA46061A (fr) | Traitement ascaroside de maladies auto-immunes et inflammatoires | |
| MA42930A (fr) | Traitement de maladies neurodégénératives | |
| MA47820A (fr) | Traitement de la glycogénose de type iii | |
| DK3142664T3 (da) | Sammensætninger og fremgangsmåder til behandling og diagnosticering af øjensygdomme | |
| MA41462A (fr) | Méthode de traitement de maladies | |
| MA43314A (fr) | Vecteurs de grippe atténues utilisés pour la prophylaxie et/ou le traitement de maladies infectieuses ainsi que pour le traitement de maladies oncologiques | |
| MA53127A (fr) | Utilisation de stimulateurs gcs pour le traitement de maladies mitochondriales | |
| HK1249016A1 (zh) | 使用抗il-34抗體治療神經疾病的組合物和方法 | |
| MA53568A (fr) | Médicaments pour le traitement de maladies ophtalmiques | |
| DK3157522T3 (da) | Muskarin-antagonister og kombinationer deraf til behandlingen af luftvejssygdomme i heste | |
| HK1258994A1 (zh) | 用於疾病治療的方法 | |
| FR3017298B1 (fr) | Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires |